Does treatment with l-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?
Cite this article as: Jaeschke, R., Guyatt, G., Gerstein, H. et al. J Gen Intern Med (1996) 11: 744. doi:10.1007/BF02598988 Abstract OBJECTIVE: To determine if health-related quality of life (HRQL) in patients of middle age and older with elevated thyroid-stimulating hormone (TSH) and normal total thyroid hormone levels—subclinical hypothyroidism—improves with l-thyroxine replacement therapy. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Outpatient clinic. PATIENTS: Thirty-seven patients with subclinical hypothyroidism, most with symptoms consistent with hypothyroidism, over 55 years of age. INTERVEJVTIOJVS: Placebo or L-thyroxine replacement therapy to achieve normal TSH level. MEASUREMENTS AND MAIN RESULTS: Disease-specific and general HRQL, cognitive function, bone mineral density, lipid levels. The mean daily dose of L-thyroxine replacement in the active group was 68±21 µg. TSH decreased by 8.6 mIU/L (95% confidence interval [CI] 4.1 to 13.1) and T 4 increased by 27.9 nmol/L (95% CI 14.8 to 41.2). There was a statistically significant improvement in a composite psychometric memory score in treated versus control patients; all other outcomes showed similar findings in the two groups. Although confidence intervals for most measures did not exclude an important improvement in HRQL with thyroid replacement, no measure of symptoms or HRQL either showed clinically important trends in favor of treatment, or approached conventional levels of statistical significance. CONCLUSIONS: In middle-aged and older patients with elevated TSH and normal T 4, it may not be harmful to follow biochemical and clinical status even in the presence of nonspecific symptoms potentially associated with hypothyroidism. Key words Subclinical hypothyroidism quality of life elderly
Supported by a grant from Ontario Ministry of Health and by a grant from Boots Pharmaceuticals. Medication and placebo was provided by Boots Pharmaceuticals.
Utiger RD. Thyrotropin releasing hormone and thyrotropin secretion. J Lab Clin Med. 1987;109:327–35.
Larsen PR. Thyroid-pituitary interaction. Thyroid regulation of thyrotropin secretion by thyroid hormones. N Engl J Med. 1982;306:23–32.
Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyroidism. BMJ. 1973;1:290–3.
Cooper DS, Utiger RD, Larsen PR, Ross DS. Subclinical hypothyroidism. Lancet. 1986;251–2. Editorial.
Cooper DS. Subclinical hypothyroidism. JAMA. 1987;258:246–7. Editorial.
Turnbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Wickhan survey. Clin Endocrinol (Oxf). 1977;7:481–93.
Rosenthal MJ, Hunt WC, Garry PJ, et al. Thyroid function in the elderly: microsomal antibodies as discriminant for therapy. JAMA. 1987;258:209–13.
Pacchiarotti A, Martino E, Bartalena L, et al. Serum free thyroid hormones in subclinical hypothyroidism. J Endocrinol Invest. 1986;9:315–9.
Ferrara C, Paracchi E, Parisio E, et al. Serum free thyroid hormones in different degrees of hypothyroidism and in euthyroid autoimmune thyroiditis. Acta Endocrinol (Copenh). 1987;114:559–64.
Bell GM, Todd WTA, Forfar JC, et al. End-organ responses to thyroxine in subclinical hypothyroidism. Clin Endocrinol (Oxf). 1985;22:83–9.
Forfar JC, Wathem CG, Todd WT, et al. Left ventricular performance in subclinical hypothyroidism. QJM. 1985;57:857–65.
Cooper DS, Halpem R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double blind, placebo controlled trial. Ann Intern Med. 1984;101:18–24.
Ridgway EC, Cooper DS, Walker H, Rodbard D, Haloof F. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1981;53:1238–42.
Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg P-A, Lindstedt G. A double-blind cross-over 12-month study of
l-thyroxine treatment of women with “subclinical” hypothyroidism. Clin Endocrinol. 1988;29:63–76.
Campbell AJ. Thyroid disorders in the elderly. Difficulties in diagnosis and treatment. Drugs. 1986;31:455–61.
Bansal SK, Sahi SP, Basu SK. Old JM. Hypothyroidism in elderly males—an under diagnosis. Br J Clin Pract. 1986;40:17–8.
Bahemuka M, Hodkinson HM. Screening for hypothyroidism in elderly Inpatients. BMJ. 1975;2:601–3.
Felicetta JV. Thyroid changes with aging: significance and management. Geriatrics. 1987;42:86–8,91–2.
Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med. 1987;82:1167–70.
Coindre JM, David JP, Riviere L, et al. Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med. 1986;146:48–53.
Ross DS. Bone density is not reduced during the short-term administration of levo-thyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med. 1993;95:38–58.
Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316:764–70.
Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC. Spectrum of quality of life impairment in hypothyroidism. Qual Life Res. 1994;3:323–7.
Jaeschke R, Stager J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.
Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol. 1994;47:81–7.
Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46.
Bergner M, Robbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of health status measure. Med Care. 1981;19:797–805.
Rockey PH, Griep RJ. Behavioral dysfunction in hyperthyroidism. Improvement with treatment. Arch Intern Med. 1980;140:1194–7.
Lezak MD. Neuropsychological Assessment. 2nd ed. New York, NY: Oxford University Press; 1983.
Spreen O, Strauss E. Compendium of Neuropsychological Tests. New York, NY: Oxford University Press; 1991.
Molloy DW, Beerschoken DA, Borrie MJ, Crilly RG, Cape RDT. Acute effects of exercise on neuropsychological function in elderly subjects. J Am Geriatr Soc. 1988;36:29–33.
Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;97:1311–20.
Webber C. Some factors which influence the evaluation of dual photon measurement of lumbar spine bone mineral mass. J Can Assoc Radiol. 1989;40:87–91.
Nottestad SY, Baumel JJ, Kimmel DB, Recker RR, Henney RP. The proportion of trabecular bone in human vertebrae. J Bone Miner Res. 1987;2:221–9.
PubMed CrossRef Copyright information
© Blackwell Science, Inc. 1996